| Project/Area Number |
26670514
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Embryonic/Neonatal medicine
|
|---|
| Research Institution | Osaka City University |
|---|
Principal Investigator |
Saito Mika 大阪市立大学, 大学院医学研究科, 講師 (40419700)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
徳原 大介 大阪市立大学, 大学院医学研究科, 講師 (60448751)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | ワクチン / アジュバント / 新生児 / 自然免疫 / RSウイルス / ウイルス / 臍帯血 / 感染症 |
|---|
| Outline of Final Research Achievements |
Adjuvant is necessary for the development of vaccine against RSV, because the immune response against recombinant RSV protein is weak in neonates and adults. Zymosan, a cell wall extract from Saccharomyces cervisiae, gave comparable innate immune response via TLR2/TLR6 heterodimer in the immune cells of cord blood and adult blood, thus may be useful as a nasal vaccine adjuvant against RSV in neonates and infants.
|
